Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Descripció completa

Dades bibliogràfiques

Autors principals:	Thomas Mika, Katharina Strate, Swetlana Ladigan, Clemens Aigner, Uwe Schlegel, Iris Tischoff, Sabine Tischer-Zimmermann, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Roland Schroers
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2019-12-01
Col·lecció:	Frontiers in Medicine
Matèries:	PTLD alloHSCT aggressive lymphoma brentuximab vedotin (BV) third-party EBV-specific T-lymphocytes
Accés en línia:	https://www.frontiersin.org/article/10.3389/fmed.2019.00295/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!